Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

Dr. Sleeman has more than two decades of experience as an R&D leader and scientist in inflammatory disease and cancer. His career has encompassed the research and development of six FDA-approved ...

Cambridge biotech company Mestag Therapeutics has appointed experienced executive Dr Matthew Sleeman as Chief Scientific Officer. Mestag is harnessing fibroblast immunology for patients with ...

Kiniksa (KNSA) plans to discontinue the development of abiprubart in Sjogren’s Disease. The company will explore strategic alternatives for the ...

Mestag Therapeutics ("Mestag"), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...